Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchQuercetinQuercetin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Discovery of the covalent SARS‐CoV‐2 Mpro inhibitors from antiviral herbs via integrating target‐based high‐throughput screening and chemoproteomic approaches

Zhang et al., Journal of Medical Virology, doi:10.1002/jmv.29208
Nov 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Quercetin for COVID-19
24th treatment shown to reduce risk in July 2021, now with p = 0.002 from 12 studies.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 112 treatments. c19early.org
In Vitro study showing that quercetin can potently inhibit SARS-CoV-2 Mpro activity. Screening of 60 antiviral herbs showed Lonicera japonica extract inhibited Mpro in a time-dependent manner, indicating the presence of covalent cysteine-binding inhibitors. UHPLC-HRMS analysis identified 22 Lonicera japonica components that could covalently bind and inhibit Mpro, including quercetin. Biochemical assays validated quercetin as an Mpro inhibitor, with an IC50 of 9.44μM after 63 minutes preincubation. Inactivation kinetics showed quercetin irreversibly inhibits Mpro in a time- and dose-dependent manner. Surface plasmon resonance analysis determined quercetin's binding affinity for Mpro with a KD of 0.308μM. The study highlights an integrative screening approach to identify antiviral compounds from herbs and specifically demonstrates quercetin's potential as an irreversible covalent inhibitor targeting the SARS-CoV-2 main protease.
Bioavailability. Quercetin has low bioavailability and studies typically use advanced formulations to improve bioavailability which may be required to reach therapeutic concentrations.
73 preclinical studies support the efficacy of quercetin for COVID-19:
In Silico studies predict inhibition of SARS-CoV-2, or minimization of side effects, with quercetin or metabolites via binding to the spikeA,3,9,10,22,24,25,30,38,39,41,42,62-64, MproB,3,7,9,11,13,15,17,18,20,23,24,30,34,36-38,42,43,45,63-65, RNA-dependent RNA polymeraseC,1,3,9,32,64, PLproD,3,37,45, ACE2E,22,23,28,37,41,63, TMPRSS2F,22, nucleocapsidG,3, helicaseH,3,29,34, endoribonucleaseI,39, NSP16/10J,6, cathepsin LK,26, Wnt-3L,22, FZDM,22, LRP6N,22, ezrinO,40, ADRPP,38, NRP1Q,41, EP300R,16, PTGS2S,23, HSP90AA1T,16,23, matrix metalloproteinase 9U,31, IL-6V,21,35, IL-10W,21, VEGFAX,35, and RELAY,35 proteins. In Vitro studies demonstrate inhibition of the MproB,15,46,51,59 protein, and inhibition of spike-ACE2 interactionZ,47. In Vitro studies demonstrate efficacy in Calu-3AA,50, A549AB,21, HEK293-ACE2+AC,58, Huh-7AD,25, Caco-2AE,49, Vero E6AF,19,42,49, mTECAG,52, and RAW264.7AH,52 cells. Animal studies demonstrate efficacy in K18-hACE2 miceAI,55, db/db miceAJ,52,61, BALB/c miceAK,60, and rats66. Quercetin reduced proinflammatory cytokines and protected lung and kidney tissue against LPS-induced damage in mice60, inhibits LPS-induced cytokine storm by modulating key inflammatory and antioxidant pathways in macrophages5, and inhibits SARS-CoV-2 ORF3a ion channel activity, which contributes to viral pathogenicity and cytotoxicity54.
a. The trimeric spike (S) protein is a glycoprotein that mediates viral entry by binding to the host ACE2 receptor, is critical for SARS-CoV-2's ability to infect host cells, and is a target of neutralizing antibodies. Inhibition of the spike protein prevents viral attachment, halting infection at the earliest stage.
b. The main protease or Mpro, also known as 3CLpro or nsp5, is a cysteine protease that cleaves viral polyproteins into functional units needed for replication. Inhibiting Mpro disrupts the SARS-CoV-2 lifecycle within the host cell, preventing the creation of new copies.
c. RNA-dependent RNA polymerase (RdRp), also called nsp12, is the core enzyme of the viral replicase-transcriptase complex that copies the positive-sense viral RNA genome into negative-sense templates for progeny RNA synthesis. Inhibiting RdRp blocks viral genome replication and transcription.
d. The papain-like protease (PLpro) has multiple functions including cleaving viral polyproteins and suppressing the host immune response by deubiquitination and deISGylation of host proteins. Inhibiting PLpro may block viral replication and help restore normal immune responses.
e. The angiotensin converting enzyme 2 (ACE2) protein is a host cell transmembrane protein that serves as the cellular receptor for the SARS-CoV-2 spike protein. ACE2 is expressed on many cell types, including epithelial cells in the lungs, and allows the virus to enter and infect host cells. Inhibition may affect ACE2's physiological function in blood pressure control.
f. Transmembrane protease serine 2 (TMPRSS2) is a host cell protease that primes the spike protein, facilitating cellular entry. TMPRSS2 activity helps enable cleavage of the spike protein required for membrane fusion and virus entry. Inhibition may especially protect respiratory epithelial cells, buy may have physiological effects.
g. The nucleocapsid (N) protein binds and encapsulates the viral genome by coating the viral RNA. N enables formation and release of infectious virions and plays additional roles in viral replication and pathogenesis. N is also an immunodominant antigen used in diagnostic assays.
h. The helicase, or nsp13, protein unwinds the double-stranded viral RNA, a crucial step in replication and transcription. Inhibition may prevent viral genome replication and the creation of new virus components.
i. The endoribonuclease, also known as NendoU or nsp15, cleaves specific sequences in viral RNA which may help the virus evade detection by the host immune system. Inhibition may hinder the virus's ability to mask itself from the immune system, facilitating a stronger immune response.
j. The NSP16/10 complex consists of non-structural proteins 16 and 10, forming a 2'-O-methyltransferase that modifies the viral RNA cap structure. This modification helps the virus evade host immune detection by mimicking host mRNA, making NSP16/10 a promising antiviral target.
k. Cathepsin L is a host lysosomal cysteine protease that can prime the spike protein through an alternative pathway when TMPRSS2 is unavailable. Dual targeting of cathepsin L and TMPRSS2 may maximize disruption of alternative pathways for virus entry.
l. Wingless-related integration site (Wnt) ligand 3 is a host signaling molecule that activates the Wnt signaling pathway, which is important in development, cell growth, and tissue repair. Some studies suggest that SARS-CoV-2 infection may interfere with the Wnt signaling pathway, and that Wnt3a is involved in SARS-CoV-2 entry.
m. The frizzled (FZD) receptor is a host transmembrane receptor that binds Wnt ligands, initiating the Wnt signaling cascade. FZD serves as a co-receptor, along with ACE2, in some proposed mechanisms of SARS-CoV-2 infection. The virus may take advantage of this pathway as an alternative entry route.
n. Low-density lipoprotein receptor-related protein 6 is a cell surface co-receptor essential for Wnt signaling. LRP6 acts in tandem with FZD for signal transduction and has been discussed as a potential co-receptor for SARS-CoV-2 entry.
o. The ezrin protein links the cell membrane to the cytoskeleton (the cell's internal support structure) and plays a role in cell shape, movement, adhesion, and signaling. Drugs that occupy the same spot on ezrin where the viral spike protein would bind may hindering viral attachment, and drug binding could further stabilize ezrin, strengthening its potential natural capacity to impede viral fusion and entry.
p. The Adipocyte Differentiation-Related Protein (ADRP, also known as Perilipin 2 or PLIN2) is a lipid droplet protein regulating the storage and breakdown of fats in cells. SARS-CoV-2 may hijack the lipid handling machinery of host cells and ADRP may play a role in this process. Disrupting ADRP's interaction with the virus may hinder the virus's ability to use lipids for replication and assembly.
q. Neuropilin-1 (NRP1) is a cell surface receptor with roles in blood vessel development, nerve cell guidance, and immune responses. NRP1 may function as a co-receptor for SARS-CoV-2, facilitating viral entry into cells. Blocking NRP1 may disrupt an alternative route of viral entry.
r. EP300 (E1A Binding Protein P300) is a transcriptional coactivator involved in several cellular processes, including growth, differentiation, and apoptosis, through its acetyltransferase activity that modifies histones and non-histone proteins. EP300 facilitates viral entry into cells and upregulates inflammatory cytokine production.
s. Prostaglandin G/H synthase 2 (PTGS2, also known as COX-2) is an enzyme crucial for the production of inflammatory molecules called prostaglandins. PTGS2 plays a role in the inflammatory response that can become severe in COVID-19 and inhibitors (like some NSAIDs) may have benefits in dampening harmful inflammation, but note that prostaglandins have diverse physiological functions.
t. Heat Shock Protein 90 Alpha Family Class A Member 1 (HSP90AA1) is a chaperone protein that helps other proteins fold correctly and maintains their stability. HSP90AA1 plays roles in cell signaling, survival, and immune responses. HSP90AA1 may interact with numerous viral proteins, but note that it has diverse physiological functions.
u. Matrix metalloproteinase 9 (MMP9), also called gelatinase B, is a zinc-dependent enzyme that breaks down collagen and other components of the extracellular matrix. MMP9 levels increase in severe COVID-19. Overactive MMP9 can damage lung tissue and worsen inflammation. Inhibition of MMP9 may prevent excessive tissue damage and help regulate the inflammatory response.
v. The interleukin-6 (IL-6) pro-inflammatory cytokine (signaling molecule) has a complex role in the immune response and may trigger and perpetuate inflammation. Elevated IL-6 levels are associated with severe COVID-19 cases and cytokine storm. Anti-IL-6 therapies may be beneficial in reducing excessive inflammation in severe COVID-19 cases.
w. The interleukin-10 (IL-10) anti-inflammatory cytokine helps regulate and dampen immune responses, preventing excessive inflammation. IL-10 levels can also be elevated in severe COVID-19. IL-10 could either help control harmful inflammation or potentially contribute to immune suppression.
x. Vascular Endothelial Growth Factor A (VEGFA) promotes the growth of new blood vessels (angiogenesis) and has roles in inflammation and immune responses. VEGFA may contribute to blood vessel leakiness and excessive inflammation associated with severe COVID-19.
y. RELA is a transcription factor subunit of NF-kB and is a key regulator of inflammation, driving pro-inflammatory gene expression. SARS-CoV-2 may hijack and modulate NF-kB pathways.
z. The interaction between the SARS-CoV-2 spike protein and the human ACE2 receptor is a primary method of viral entry, inhibiting this interaction can prevent the virus from attaching to and entering host cells, halting infection at an early stage.
aa. Calu-3 is a human lung adenocarcinoma cell line with moderate ACE2 and TMPRSS2 expression and SARS-CoV-2 susceptibility. It provides a model of the human respiratory epithelium, but many not be ideal for modeling early stages of infection due to the moderate expression levels of ACE2 and TMPRSS2.
ab. A549 is a human lung carcinoma cell line with low ACE2 expression and SARS-CoV-2 susceptibility. Viral entry/replication can be studied but the cells may not replicate all aspects of lung infection.
ac. HEK293-ACE2+ is a human embryonic kidney cell line engineered for high ACE2 expression and SARS-CoV-2 susceptibility.
ad. Huh-7 cells were derived from a liver tumor (hepatoma).
ae. Caco-2 cells come from a colorectal adenocarcinoma (cancer). They are valued for their ability to form a polarized cell layer with properties similar to the intestinal lining.
af. Vero E6 is an African green monkey kidney cell line with low/no ACE2 expression and high SARS-CoV-2 susceptibility. The cell line is easy to maintain and supports robust viral replication, however the monkey origin may not accurately represent human responses.
ag. mTEC is a mouse tubular epithelial cell line.
ah. RAW264.7 is a mouse macrophage cell line.
ai. A mouse model expressing the human ACE2 receptor under the control of the K18 promoter.
aj. A mouse model of obesity and severe insulin resistance leading to type 2 diabetes due to a mutation in the leptin receptor gene that impairs satiety signaling.
ak. A mouse model commonly used in infectious disease and cancer research due to higher immune response and susceptibility to infection.
Zhang et al., 10 Nov 2023, peer-reviewed, 11 authors. Contact: xyzhuang59@foxmail.com, geguangbo@shutcm.edu.cn.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
This PaperQuercetinAll
Efficacy of mouthwash on reducing salivary SARS-CoV-2 viral load and clinical symptoms: a systematic review and meta-analysis
Mingrui Zhang, Nan Meng, Hong Duo, Yuanbo Yang, Qing Dong, Jianqi Gu
BMC Infectious Diseases, doi:10.1186/s12879-023-08669-z
Background COVID-19 has been a public health emergency of international concern (PHEIC) for a lengthy period of time. The novel coronavirus is primarily spread via aerosols at a short distance, with infected individuals releasing large amounts of aerosols when speaking and coughing. However, there is an open question regarding whether mouthwash could effectively reduce virus transmission during the COVID-19 pandemic and support the prevention of infection among medical workers. Methods Cochrane Library, PubMed, Web of Science, and Embase databases were systematically searched from the inception of each database to January 12, 2023 for currently available randomized clinical trials (RCTs) on the effect of mouthwash on novel coronavirus load in the oral cavity in COVID-19 patients. The treatment group received mouthwash for rinsing the mouth, while the control group received a placebo or distilled water for COVID-19 patients. The primary outcomes were CT value and viral load. Odds ratios (ORs) were estimated using a random-effects model. Subgroup and sensitivity analyses were performed to minimize the bias and the impact of heterogeneity. Results Thirteen RCTs were included. Seven studies reported the intervention effect of mouthwash on the CT value of novel coronavirus. The analysis results showed that the mouthwash group had a positive impact on the CT value of novel coronavirus [ SMD = 0.35, 95% CI (0.21, 0.50)] compared with the control group. In addition, subgroup analysis showed a significant positive effect of mouthwash on CT values in the treatment group compared with the control group, with chlorhexidine (CHX) [SMD = 0.33, 95% CI (0.10, 0.56)], povidone-iodine (PVP-I) [SMD = 0.61, 95% CI (0.23, 0.99)], or hydrogen peroxide (HP) [SMD = 1.04, 95% CI (0.30, 1.78)] as an ingredient of the mouthwash. Six studies reported the intervention effect of mouthwash on the viral load, 263 cases in the treatment group and 164 cases in the control group. The analysis results showed that there was no statistical difference between the mouthwash group and the control group in the viral load of novel coronavirus [SMD = -0.06, 95% CI (-0.18, 0.05)]. In the subgroup analysis by measurement time, there were statistically significant differences between the mouthwash and control groups for CT values [SMD = 0.52, 95% CI (0.31, 0.72)] and viral load [SMD = -0.32, 95% CI (-0.56, -0.07)] within 30 min of gargling.
Supplementary Information The online version contains supplementary material available at https:// doi. org/ 10. 1186/ s12879-023-08669-z. Additional file 6: Table S1 . Search strategy. Authors' contributions Conceptualization: Qing Dong, Jianqi Gu; Methodology: Nan Meng, Mingrui Zhang, Hong Duo; Formal analysis and investigation: Nan Meng, Mingrui Zhang, Hong Duo, Yuanbo Yang; Writing-original draft preparation: Mingrui Zhang, Nan Meng; Writing-review and editing: Qing Dong, Jianqi Gu; Funding acquisition: Qing Dong, Yuanbo Yang; Resources: Qing Dong, Yuanbo Yang; Supervision: Qing Dong, Jianqi Gu. And all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. Declarations Ethics approval and consent to participate All analyses were based on previous published studies, thus no ethical approval and patient consent are required. Consent for publication Not applicable. Competing interests The authors declare no competing interests. • fast, convenient online submission • thorough peer review by experienced researchers in your field • rapid publication on acceptance • support for research data, including large and complex data types • gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year • At BMC, research is always in progress. Learn more biomedcentral.com/submissions Ready to submit your research Ready to submit your..
References
Alemany, Perez-Zsolt, Raïch-Regué, Muñoz-Basagoiti, Ouchi et al., Cetylpyridinium chloride mouthwash to reduce shedding of infectious SARS-CoV-2: a double-blind randomized clinical trial, J Dent Res
Alzahrani, Bamashmous, Alkharobi, Alghamdi, Alharbi et al., Mouth rinses efficacy on salivary SARS-CoV-2 viral load: a randomized clinical trial, J Med Virol
Arteagoitia, Andrés, Ramos, Does chlorhexidine reduce bacteremia following tooth extraction? A systematic review and metaanalysis, PLoS ONE
Ather, Patel, Ruparel, Diogenes, Hargreaves, Coronavirus Disease 19 (COVID-19): Implications for clinical dental care, J Endodontics
Barrueco, Moreno, Martínez-Beneyto, García-Vázquez, González et al., Effect of oral antiseptics in reducing SARS-CoV-2 infectivity: evidence from a randomized double-blind clinical trial, Emerg Microbes Infect
Bidra, Pelletier, Westover, Frank, Brown et al., Comparison of In Vitro Inactivation of SARS CoV-2 with Hydrogen Peroxide and Povidone-Iodine Oral Antiseptic Rinses, J Prosthodontics
Carrouel, Gonçalves, Conte, Campus, Fisher et al., Antiviral activity of reagents in mouth rinses against SARS-CoV-2, J Dent Res
Carrouel, Valette, Gadea, Esparcieux, Illes et al., Use of an antiviral mouthwash as a barrier measure in the SARS-CoV-2 transmission in adults with asymptomatic to mild COVID-19: a multicentre, randomized, double-blind controlled trial, Clin Microbiol Infect
Cavalcante-Leão, De Araujo, Basso, Schroder, Guariza-Filho et al., Is there scientific evidence of the mouthwashes effectiveness in reducing viral load in Covid-19? A systematic review, J Clin Exp Dent
Chen, Chang, The effectiveness of mouthwash against SARS-CoV-2 infection: A review of scientific and clinical evidence, J Formosan Med Assoc =Taiwan Yi Zhi
Costa, Brites, Vaz, De Santana, Santos et al., Chlorhexidine mouthwash reduces the salivary viral load of SARS-CoV-2: a randomized clinical trial, Oral Dis
Da Fonseca Orcina, Vilhena, De, Oliveira, Da et al., A Phthalocyanine derivate mouthwash to gargling/rinsing as an option to reduce clinical symptoms of COVID-19: case series, Clin Cosmetic Invest Dentistry
Da, Santos, Da Fonseca, Machado, Vilhena et al., Beneficial effects of a mouthwash containing an antiviral phthalocyanine derivative on the length of hospital stay for COVID-19: randomised trial, Sci Rep
Davis, Mccorkell, Vogel, Topol, Long COVID: major findings, mechanisms and recommendations, Nat Rev Microbiol
Eduardo, Corrêa, Heller, Daep, Benitez et al., Salivary SARS-CoV-2 load reduction with mouthwash use: a randomized pilot clinical trial, Heliyon
Elzein, Sater, Fakhreddine, Hanna, Feghali et al., In vivo evaluation of the virucidal efficacy of chlorhexidine and povidone-iodine mouthwashes against salivary SARS-CoV-2. A randomized-controlled clinical trial, J Evid-Based Dental Pract
Fernandez, Guedes, Langa, Rösing, Cavagni et al., Virucidal efficacy of chlorhexidine: a systematic review, Odontology
Ferrer, Barrueco, Martinez-Beneyto, Moreno, Ausina-Márquez et al., Clinical evaluation of antiseptic mouth rinses to reduce salivary load of SARS-CoV-2, Sci Rep
Garcia-Sanchez, Peña-Cardelles, Salgado-Peralvo, Robles, Ordonez-Fernandez et al., Virucidal activity of different mouthwashes against the salivary load of SARS-CoV-2: a narrative review, Healthc
Gray, Katelaris, Lipson, Recurrent anaphylaxis caused by topical povidone-iodine (Betadine), J Paediatr Child Health
Gül, Dilsiz, Sağlık, Aydın, Effect of oral antiseptics on the viral load of SARS-CoV-2: a randomized controlled trial, Dental Med Prob
Hernández-Vásquez, Barrenechea-Pulache, Comandé, Azañedo, Mouthrinses and SARS-CoV-2 viral load in saliva: a living systematic review, Evid Based Dent, doi:10.1038/s41432-022-0253-z
Huang, Huang, Use of chlorhexidine to eradicate oropharyngeal SARS-CoV-2 in COVID-19 patients, J Med Virol
Huang, Pérez, Kato, Mikami, Okuda et al., SARS-CoV-2 infection of the oral cavity and saliva, Nat Med
Idrees, Mcgowan, Fawzy, Abuderman, Balasubramaniam et al., Efficacy of Mouth Rinses and Nasal Spray in the Inactivation of SARS-CoV-2: A Systematic Review and Meta-Analysis of In Vitro and In Vivo Studies, Int J Environ Res Public Health
Joynt, Wu, Understanding COVID-19: what does viral RNA load really mean?, Lancet Infect Dis
Kohn, Collins, Cleveland, Harte, Eklund et al., Guidelines for infection control in dental health-care settings-2003, MMWR Recommend Rep
Kumar, Mishra, Dunn, Townsend, Oguadinma et al., Biocides and novel antimicrobial agents for the mitigation of coronaviruses, Front Microbiol
Liberati, Altman, Tetzlaff, Mulrow, Gøtzsche et al., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration, BMJ (Clin Res Ed)
Mcvernon, Liberman, WHO keeps covid-19 a public health emergency of international concern, BMJ (Clinical Research Ed)
Meister, Gottsauner, Schmidt, Heinen, Todt et al., Mouthrinses against SARS-CoV-2 -High antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial, Virus Res
Natto, Bakhrebah, Afeef, Al-Harbi, Nassar et al., The short-term effect of different chlorhexidine forms versus povidone iodine mouth rinse in minimizing the oral SARS-CoV-2 viral load: An open label randomized controlled clinical trial study, Medicine
Pattanshetty, Narayana, Radhakrishnan, Povidone-iodine gargle as a prophylactic intervention to interrupt the transmission of SARS-CoV-2, Oral Dis
Peng, Xu, Li, Cheng, Zhou et al., Transmission routes of 2019-nCoV and controls in dental practice, Int J Oral Sci
Poleti, Gregório, Bistaffa, Fernandes, Vilhena et al., use of mouthwash and dentifrice containing an antimicrobial phthalocyanine derivative for the reduction of clinical symptoms of covid-19: a randomized triple-blind clinical trial, J Evid Based Dent Pract
Sachs, Karim, Aknin, Allen, Brosbøl et al., The Lancet Commission on lessons for the future from the COVID-19 pandemic, Lancet
Seneviratne, Balan, Ko, Udawatte, Lai et al., Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore, Infection
Tang, Schmitz, Persing, Stratton, Laboratory diagnosis of COVID-19: current issues and challenges, J Clin Microbiol
Tarragó-Gil, Mj, Salcedo, Alvarez, Ainaga et al., Randomized clinical trial to assess the impact of oral intervention with cetylpyridinium chloride to reduce salivary SARS-CoV-2 viral load, J Clin Periodontol
Wu, Leung, Leung, Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study, Lancet
Wölfel, Corman, Guggemos, Seilmaier, Zange et al., Virological assessment of hospitalized patients with COVID-2019, Nature
Xu, Zhong, Deng, Peng, Dan et al., High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa, Int J Oral Sci
Zemouri, Volgenant, Buijs, Crielaard, Rosema et al., Dental aerosols: microbial composition and spatial distribution, J Oral Microbiol
{ 'indexed': { 'date-parts': [[2023, 11, 11]], 'date-time': '2023-11-11T00:32:49Z', 'timestamp': 1699662769873}, 'reference-count': 49, 'publisher': 'Wiley', 'issue': '11', 'license': [ { 'start': { 'date-parts': [[2023, 11, 10]], 'date-time': '2023-11-10T00:00:00Z', 'timestamp': 1699574400000}, 'content-version': 'vor', 'delay-in-days': 9, 'URL': 'http://onlinelibrary.wiley.com/termsAndConditions#vor'}], 'content-domain': {'domain': ['onlinelibrary.wiley.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2023, 11]]}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>The main proteases (M<jats:sup>pro</jats:sup>) are ' 'highly conserved cysteine‐rich proteins that can be covalently modified by numerous natural ' 'and synthetic compounds. Herein, we constructed an integrative approach to efficiently ' 'discover covalent inhibitors of M<jats:sup>pro</jats:sup> from complex herbal matrices. This ' 'work begins with biological screening of 60 clinically used antiviral herbal medicines, among ' 'which <jats:italic>Lonicera japonica Flos</jats:italic> (LJF) demonstrated the strongest ' 'anti‐M<jats:sup>pro</jats:sup> effect (IC<jats:sub>50</jats:sub>\u2009=\u200937.82\u2009' 'μg/mL). Mass spectrometry (MS)‐based chemical analysis and chemoproteomic profiling revealed ' 'that LJF extract contains at least 50 constituents, of which 22 exhibited the capability to ' 'covalently modify M<jats:sup>pro</jats:sup>. We subsequently verified the ' 'anti‐M<jats:sup>pro</jats:sup> effects of these covalent binders. Gallic acid and quercetin ' 'were found to potently inhibit severe acute respiratory syndrome coronavirus 2 ' 'M<jats:sup>pro</jats:sup> in dose‐ and time‐ dependent manners, with the ' 'IC<jats:sub>50</jats:sub> values below 10\u2009µM. The inactivation kinetics, binding ' 'affinity and binding mode of gallic acid and quercetin were further characterized by ' 'fluorescence resonance energy transfer, surface plasmon resonance, and covalent docking ' 'simulations. Overall, this study established a practical approach for efficiently discovering ' 'the covalent inhibitors of M<jats:sup>pro</jats:sup> from herbal medicines by integrating ' 'target‐based high‐throughput screening and MS‐based assays, which would greatly facilitate ' 'the discovery of key antiviral constituents from medicinal plants.</jats:p>', 'DOI': '10.1002/jmv.29208', 'type': 'journal-article', 'created': { 'date-parts': [[2023, 11, 10]], 'date-time': '2023-11-10T12:06:23Z', 'timestamp': 1699617983000}, 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Discovery of the covalent SARS‐CoV‐2 M<sup>pro</sup> inhibitors from antiviral herbs via ' 'integrating target‐based high‐throughput screening and chemoproteomic approaches', 'prefix': '10.1002', 'volume': '95', 'author': [ { 'given': 'Ya‐Ni', 'family': 'Zhang', 'sequence': 'first', 'affiliation': [ { 'name': 'Shanghai Frontiers Science Center of TCM Chemical Biology, ' 'Institute of Interdisciplinary Integrative Medicine Research ' 'Shanghai University of Traditional Chinese Medicine Shanghai ' 'China'}]}, { 'given': 'Guang‐Hao', 'family': 'Zhu', 'sequence': 'additional', 'affiliation': [ { 'name': 'Shanghai Frontiers Science Center of TCM Chemical Biology, ' 'Institute of Interdisciplinary Integrative Medicine Research ' 'Shanghai University of Traditional Chinese Medicine Shanghai ' 'China'}]}, { 'given': 'Wei', 'family': 'Liu', 'sequence': 'additional', 'affiliation': [ { 'name': 'Shuguang Hospital Affiliated to Shanghai University of ' 'Traditional Chinese Medicine Shanghai China'}]}, { 'given': 'Xi‐Xiang', 'family': 'Chen', 'sequence': 'additional', 'affiliation': [ { 'name': 'Shanghai Frontiers Science Center of TCM Chemical Biology, ' 'Institute of Interdisciplinary Integrative Medicine Research ' 'Shanghai University of Traditional Chinese Medicine Shanghai ' 'China'}]}, { 'given': 'Yuan‐Yuan', 'family': 'Xie', 'sequence': 'additional', 'affiliation': [ { 'name': 'Academy of Integrative Medicine Shanghai University of ' 'Traditional Chinese Medicine Shanghai China'}]}, { 'given': 'Jian‐Rong', 'family': 'Xu', 'sequence': 'additional', 'affiliation': [ { 'name': 'Academy of Integrative Medicine Shanghai University of ' 'Traditional Chinese Medicine Shanghai China'}]}, { 'given': 'Mei‐Fang', 'family': 'Jiang', 'sequence': 'additional', 'affiliation': [ { 'name': 'Shanghai Frontiers Science Center of TCM Chemical Biology, ' 'Institute of Interdisciplinary Integrative Medicine Research ' 'Shanghai University of Traditional Chinese Medicine Shanghai ' 'China'}]}, { 'given': 'Xiao‐Yu', 'family': 'Zhuang', 'sequence': 'additional', 'affiliation': [ { 'name': 'Shanghai Frontiers Science Center of TCM Chemical Biology, ' 'Institute of Interdisciplinary Integrative Medicine Research ' 'Shanghai University of Traditional Chinese Medicine Shanghai ' 'China'}]}, { 'given': 'Wei‐Dong', 'family': 'Zhang', 'sequence': 'additional', 'affiliation': [ { 'name': 'Shanghai Frontiers Science Center of TCM Chemical Biology, ' 'Institute of Interdisciplinary Integrative Medicine Research ' 'Shanghai University of Traditional Chinese Medicine Shanghai ' 'China'}]}, { 'given': 'Hong‐Zhuan', 'family': 'Chen', 'sequence': 'additional', 'affiliation': [ { 'name': 'Shanghai Frontiers Science Center of TCM Chemical Biology, ' 'Institute of Interdisciplinary Integrative Medicine Research ' 'Shanghai University of Traditional Chinese Medicine Shanghai ' 'China'}, { 'name': 'Academy of Integrative Medicine Shanghai University of ' 'Traditional Chinese Medicine Shanghai China'}]}, { 'given': 'Guang‐Bo', 'family': 'Ge', 'sequence': 'additional', 'affiliation': [ { 'name': 'Shanghai Frontiers Science Center of TCM Chemical Biology, ' 'Institute of Interdisciplinary Integrative Medicine Research ' 'Shanghai University of Traditional Chinese Medicine Shanghai ' 'China'}]}], 'member': '311', 'published-online': {'date-parts': [[2023, 11, 10]]}, 'reference': [ {'key': 'e_1_2_10_2_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.csbj.2021.08.036'}, {'key': 'e_1_2_10_3_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/v13020308'}, { 'issue': '2', 'key': 'e_1_2_10_4_1', 'first-page': '143', 'article-title': 'Pomegranate peel extract inhibits internalization and replication of ' 'the influenza virus: an in vitro study', 'volume': '10', 'author': 'Moradi M‐T', 'year': '2020', 'journal-title': 'Avicenna J Phytomed'}, { 'issue': '4', 'key': 'e_1_2_10_5_1', 'first-page': '268', 'article-title': 'Inhibitory effect of Bergenia ligulata on influenza virus A', 'volume': '58', 'author': 'Rajbhandari M', 'year': '2003', 'journal-title': 'Pharmazie'}, {'key': 'e_1_2_10_6_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/molecules22101738'}, {'key': 'e_1_2_10_7_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/molecules24234219'}, {'key': 'e_1_2_10_8_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jpha.2019.09.005'}, { 'key': 'e_1_2_10_9_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2012.10.006'}, {'key': 'e_1_2_10_10_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1625/jcam.8.1'}, {'key': 'e_1_2_10_11_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fchem.2021.819165'}, {'key': 'e_1_2_10_12_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/science.abg5827'}, { 'key': 'e_1_2_10_13_1', 'doi-asserted-by': 'crossref', 'first-page': '3144', 'DOI': '10.1182/blood-2021-153513', 'article-title': 'Inhibition of Sars‐Cov‐2 viral replication and in vivo thrombus ' 'formation by a novel plant flavonoid', 'volume': '138', 'author': 'Yang M', 'year': '2021', 'journal-title': 'Blood'}, {'key': 'e_1_2_10_14_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/mco2.151'}, {'key': 'e_1_2_10_15_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1107/S2052252520012634'}, { 'key': 'e_1_2_10_16_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41467-021-23751-3'}, { 'key': 'e_1_2_10_17_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijbiomac.2021.07.167'}, { 'issue': '4', 'key': 'e_1_2_10_18_1', 'doi-asserted-by': 'crossref', 'DOI': '10.1128/mBio.02094-21', 'article-title': 'Regulation of the dimerization and activity of SARS‐CoV‐2 main protease ' 'through reversible glutathionylation of cysteine 300', 'volume': '12', 'author': 'Davis DA', 'year': '2021', 'journal-title': 'mBio'}, {'key': 'e_1_2_10_19_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1039/D1SC03526F'}, { 'issue': '1', 'key': 'e_1_2_10_20_1', 'doi-asserted-by': 'crossref', 'first-page': '58', 'DOI': '10.1021/acs.jmedchem.1c01719', 'article-title': 'Discovery of cysteine‐targeting covalent protein kinase inhibitors', 'volume': '65', 'author': 'Lu X', 'year': '2021', 'journal-title': 'J Med Chem'}, {'key': 'e_1_2_10_21_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/acs.jcim.9b01138'}, { 'key': 'e_1_2_10_22_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s13578-021-00564-x'}, { 'key': 'e_1_2_10_23_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ejmech.2022.114130'}, {'key': 'e_1_2_10_24_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/smsc.202100124'}, {'key': 'e_1_2_10_25_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jmv.28542'}, { 'key': 'e_1_2_10_26_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.phymed.2023.154796'}, {'key': 'e_1_2_10_27_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fchem.2021.740702'}, { 'key': 'e_1_2_10_28_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/07391102.2020.1831610'}, { 'issue': '7', 'key': 'e_1_2_10_29_1', 'first-page': '1705', 'article-title': 'Trace therapeutic substances of traditional Chinese medicine: great ' 'resources of innovative drugs derived from traditional Chinese Medicine', 'volume': '47', 'author': 'Xia X‐F', 'year': '2022', 'journal-title': 'Zhongguo Zhong yao za zhi'}, {'key': 'e_1_2_10_30_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/tx020079g'}, { 'key': 'e_1_2_10_31_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.talanta.2022.123824'}, {'key': 'e_1_2_10_32_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fchem.2021.692168'}, {'key': 'e_1_2_10_33_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/nmeth.1322'}, { 'key': 'e_1_2_10_34_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jinorgbio.2022.111886'}, {'key': 'e_1_2_10_35_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1107/S2052252520012634'}, { 'key': 'e_1_2_10_36_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.foodchem.2021.131594'}, {'key': 'e_1_2_10_37_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/mco2.151'}, {'key': 'e_1_2_10_38_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/anie.202110027'}, { 'key': 'e_1_2_10_39_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/acs.jmedchem.2c01627'}, {'key': 'e_1_2_10_40_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1039/D0SC04942E'}, { 'key': 'e_1_2_10_41_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.phymed.2023.154796'}, { 'key': 'e_1_2_10_42_1', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fphar.2021.646560', 'article-title': 'Herbal medicine, gut microbiota, and COVID‐19', 'volume': '12', 'author': 'Chen Z', 'year': '2021', 'journal-title': 'Front Pharmacol'}, {'key': 'e_1_2_10_43_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1177/21649561211070483'}, {'key': 'e_1_2_10_44_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/ijerph182212001'}, {'key': 'e_1_2_10_45_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2118691'}, {'key': 'e_1_2_10_46_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/mco2.324'}, { 'key': 'e_1_2_10_47_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jpba.2021.114538'}, { 'issue': '5', 'key': 'e_1_2_10_48_1', 'first-page': '1129', 'article-title': 'Effect of Heat‐Clearing and Detoxifying Health Function of Lonicera ' 'japonica in Rats Based on Metabonomics', 'volume': '39', 'author': 'Wang YQ', 'year': '2016', 'journal-title': 'Zhong yao cai= Zhongyaocai'}, { 'issue': '22', 'key': 'e_1_2_10_49_1', 'first-page': '5407', 'article-title': 'Study of antivirus, antibacteria and immune functions of gaoreqing ' 'freeze‐dried powder', 'volume': '5', 'author': 'Xin N', 'year': '2011', 'journal-title': 'J Med Plants Res'}, {'key': 'e_1_2_10_50_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/1472-6882-12-226'}], 'container-title': 'Journal of Medical Virology', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.29208', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 11, 10]], 'date-time': '2023-11-10T12:06:32Z', 'timestamp': 1699617992000}, 'score': 1, 'resource': {'primary': {'URL': 'https://onlinelibrary.wiley.com/doi/10.1002/jmv.29208'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 11]]}, 'references-count': 49, 'journal-issue': {'issue': '11', 'published-print': {'date-parts': [[2023, 11]]}}, 'alternative-id': ['10.1002/jmv.29208'], 'URL': 'http://dx.doi.org/10.1002/jmv.29208', 'relation': {}, 'ISSN': ['0146-6615', '1096-9071'], 'subject': ['Infectious Diseases', 'Virology'], 'container-title-short': 'Journal of Medical Virology', 'published': {'date-parts': [[2023, 11]]}, 'assertion': [ { 'value': '2023-07-10', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2023-10-17', 'order': 1, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2023-11-10', 'order': 2, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit